Nmr Fragment Screening
Nmr Fragment Screening - Related Videos
09:19
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
0 Views •
Cited by 11 •
2021
Fragment-based screening by NMR is a robust method to rapidly identify small molecule binders to biomacromolecules (DNA, RNA, or proteins). Protocols describing automation-based sample preparation, NMR experiments & acquisition conditions, and analysis workflows are presented. The technique allows for optimal exploitation of both 1H and 19F NMR-active nuclei for detection.
12:28
Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
0 Views •
Cited by 8 •
2016
We provide a method to simultaneously screen a library of antibody fragments for binding affinity and cytoplasmic solubility by using the Escherichia coli twin-arginine translocation pathway, which has an inherent quality control mechanism for intracellular protein folding, to display the antibody fragments on the inner membrane.
06:17
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
0 Views •
2025
The quantitative irreversible tethering (qIT) assay is a fluorescence-based method of identifying covalent fragments that selectively engage with a target protein. Here, a detailed protocol is outlined to describe the qIT assay, with example results included.
06:29
Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
0 Views •
Cited by 19 •
2021
Crystallographic fragment screening at the Helmholtz-Zentrum Berlin is performed using a workflow with dedicated compound libraries, crystal handling tools, fast data collection facilities and largely automated data analysis. The presented protocol intends to maximize the output of such experiments to provide promising starting points for downstream structure-based ligand design.
09:24
Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
0 Views •
Cited by 2 •
2017
A simple and non-destructive technique that measures the average content of drug substances in formulated drug products containing fluorine using low-field fluorine-19 (19F) time-domain (TD) nuclear magnetic resonance (NMR) is presented here. The technique can be applied to the development and manufacturing of drugs in the pharmaceutical industry.
FAQs
Binding changes the local magnetic environment experienced by nuclei in the protein or ligand. These effects can appear as chemical-shift perturbations, which indicate altered resonance positions, or as signal broadening, which changes resonance visibility and width. Together, the patterns help identify interactions that would not be apparent from simply observing whether a compound remains present in solution.
NMR can register weak fragment binding even when the interaction does not produce a strong biochemical response. Detecting these low-affinity contacts expands the pool of starting points for medicinal chemistry. Although weak binding alone does not establish that a fragment is a useful lead, it can reveal a recognition event suitable for later structure-based design and chemical optimization.
Protein-observed experiments track changes in protein resonances when a fragment binds, whereas ligand-observed experiments monitor effects on the fragment, including altered ligand relaxation. The two approaches provide complementary ways to detect interactions and help distinguish specific binding from compounds that do not interact detectably with the target. Selecting between them depends on which molecular signal best reports the binding event.
The distribution of spectral changes can indicate where a fragment interacts with the protein and can provide clues about its interaction mode. This information helps connect a hit to a binding site rather than treating it as an isolated positive signal. Such mechanistic insight supports decisions about whether fragments should be linked, redesigned, or chemically optimized.
A typical workflow examines fragments against the target protein using protein-observed or ligand-observed NMR experiments. Researchers then evaluate chemical-shift changes, signal broadening, or altered ligand relaxation to identify binding signals and separate specific interactions from nonbinding compounds. Confirmed fragment hits can subsequently inform binding-site analysis and guide downstream lead-development strategies.
The method is useful early in drug discovery when researchers need to find small starting compounds and characterize weak interactions with a protein target. It complements biochemical assays by adding biophysical evidence about binding sites and interaction modes. The resulting information can support fragment linking and chemical optimization toward molecules with improved affinity and selectivity.